TITLE

Ask the Experts

AUTHOR(S)
Reigle, Juanita
PUB. DATE
December 2004
SOURCE
Critical Care Nurse;Dec2004, Vol. 24 Issue 6, p67
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Compares the effectivity of angiotensin-receptor blockers (ARB) and angiotensin-converting enzyme (ACE) inhibitors in treating heart failure. Effect of ACE inhibitors on the mortality and morbidity in patients with chronic heart failure and left ventricle systolic dysfunction; Complications caused by ACE inhibitors; Information on the Evaluation of Losartan in the Elderly study regarding the use of ARB in heart failure.
ACCESSION #
15351582

 

Related Articles

  • ACE inhibitors: Usual doses may be too low to lower morbidity, death. Leibovitch, Eric R. // Geriatrics;Mar97, Vol. 52 Issue 3, p76 

    Presents an abstract of the article `Do Angiotensin-Converting Enzyme Inhibitors Prolong Life in Patients with Heart Failure Treated in Clinical Practice?' by M. Packer published in the `Journal of the American College of Cardiology' dated 1996.

  • Severity of heart failure and dosage of angiotensin converting enzyme inhibitors. Clark, A.L.; Coats, A.J.S. // BMJ: British Medical Journal (International Edition);4/15/95, Vol. 310 Issue 6985, p973 

    Studies the uses of angiotensin converting enzyme inhibitors for chronic heart failure in a tertiary referral center. Investigation of the relation between the regimen used and patient variables and how this related to the dosages.

  • Stick with highest ACE inhibitor dose.  // Pulse;5/25/2011, Vol. 71 Issue 19, p9 

    The article offers information on the efficiency of low-dose angiotensin converting enzyme (ACE) inhibitors in heart failure with recommendations of titration and blood pressure monitoring.

  • Early ACE inhibitor therapy reduces risk of death after MI.  // Geriatrics;Oct93, Vol. 48 Issue 10, p24 

    Reports findings that patients who survived a myocardial infarction (MI) but have clinical evidence of congestive heart failure may benefit from early treatment with an angiotensin-converting enzyme (ACE) inhibitor.

  • Mild heart failure: Why the switch to ACE inhibitors. Khosla, Sandeep; Somberg, John // Geriatrics;Nov93, Vol. 48 Issue 11, p47 

    Discusses the benefits of angiotensin-converting enzyme (ACE) inhibitor therapy in patients with mild congestive heart failure (CHF). Mechanisms of ACE inhibitors; Common causes of CHF; Dosing strategy.

  • Consider ACE inhibitors for all CHF patients, even the very old and frail.  // Geriatrics;Mar2000, Vol. 55 Issue 3, p95 

    Presents information on a study which examined the effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. Methodology of the study; Results and discussion on the study.

  • Who benefits from medical interventions? Smith, George Davey; Egger, Matthias // BMJ: British Medical Journal (International Edition);1/8/94, Vol. 308 Issue 6921, p72 

    Investigates the risk in treating low risk patients. Significance in balancing benefits and side effects of treatments; Use of angiotensin converting enzyme inhibitors for treating and preventing heart failure; Assessment of the effects of zidovudine for the treatment of HIV.

  • ACE inhibitor receives added indication for heart failure.  // Geriatrics;Sep93, Vol. 48 Issue 9, p20 

    Reports on the approval of the use of lisinopril as adjunctive therapy for patients with congestive heart failure (CHF). Lisinopril as an angiotensin converting enzyme (ACE) inhibitor used to treat hypertension; Therapy-related symptomatic hypotension; Common adverse reactions to drug.

  • Lisinopril: A Review of its Use in Congestive Heart Failure. Simpson, K.; Jarvis, B. // Drugs;May2000, Vol. 59 Issue 5, p1149 

    The ACE inhibitor lisinopril is a lysine derivative of enalaprilat, the active metabolite of enalapril. In patients with heart failure, maximum pharmacodynamic effects are produced 6 to 8 hours after administration of the drug and persist for 12 to 24 hours. High doses (32.5 to 35mg,...

  • 533 Underuse of ACE inhibitors, beta-blockers and spironolactone in patients with heart failure is primarily due to lack of initiation of treatment. Gislason, G.H.; Rasmussen, J.N.; Abildstrom, S.Z.; Schramm, T.K.; Buch, P.; Kober, L.; Madsen, M.; Torp-Pedersen, C. // European Journal of Heart Failure. Supplements;Jun2006, Vol. 5 Issue 1, p116 

    An abstract of the study "Underuse of ACE Inhibitors, Beta-Blockers and Spironolactone in Patients With Heart Failure Is Primarily Due to Lack of Initiation of Treatment," by G. H. Gislason and colleagues is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics